Background:The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of no-reflow.Trial Registration No:SNCTP000003611Trial Status:activeEnrolling Centers:5Core Study Team: